Sagimet Biosciences, a clinical-stage biopharmaceutical company, has filed with the SEC to raise up to $75 million in an IPO for the second time. The company is focused on developing fatty acid synthase inhibitors, with its lead drug candidate, denifanstat, in development for nonalcoholic steatohepatitis. Denifanstat recently met the primary endpoint in a planned interim readout of a Phase 2b trial.